Pfizer vs. AbbVie: Comparing Dividend Yields and Growth Prospects for Income Investors

Major pharmaceutical heavyweights Pfizer and AbbVie present two very different opportunities for income-oriented investors, balancing high initial cash returns against long-term dividend growth and product portfolio resilience. Pfizer currently offers an attractive 5.9% dividend yield, allowing a $10,000 investment to generate nearly $600 annually. In contrast, AbbVie provides a lower 2.5% yield but boasts an impressive 53-year history of consecutive dividend increases, landing it among elite dividend-growth categories.

Evaluating Dividend Safety and Business Headwinds

While Pfizer's high yield is enticing, the company faces scrutiny over its financial payout metrics. Pfizer's GAAP earnings-based payout ratio sits at an alarming 246%, though that figure is inflated by one-time acquisition costs. A clearer metric is its free cash flow payout ratio of 89%. CFO Cecile Guegan affirmed during a third-quarter earnings call that operating cash flow and financial assets will comfortably support the dividend as the company navigates an upcoming patent cliff over the next couple of years.

AbbVie, meanwhile, has already weathered its own major patent cliff following the loss of exclusivity for its flagship immunology treatment, Humira, in 2023. Newer assets such as Skyrizi and Rinvoq generated a combined $23 billion in the first nine months of the year, outperforming peak Humira sales. Alongside robust neuroscience and oncology portfolios, AbbVie continues to expand its revenue base while growing its cumulative dividend by 355% since its 2013 spin-off.

What to watch next: Monitor Pfizer's late-stage pipeline advancements and free cash flow trends as it approaches its patent expirations, alongside AbbVie's ongoing sales momentum in immunology and neuroscience.